Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GIST: Molecular Profiling Suggests 2nd Therapy.

Cancer discovery - 1 Mar 2023

Abstract excerpt

In an analysis of ctDNA from patients with advanced gastrointestinal stromal tumors, researchers found that, following imatinib therapy, patients with KIT exon 11 plus 17 and/or 18 alterations had superior progression-free survival (PFS) and overall survival (OS) when they received ripretinib as a second-line treatment compared with sunitinib; patients with KIT exon 11 plus 13 and/or 14 alterations had superior...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Disease-Free Survival
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Sunitinib

Source

Identifiers

PMID: 36706070
DOI: 10.1158/2159-8290.CD-NB2023-0008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GIST: Molecular Profiling Suggests 2nd Therapy.PMID 36706070Read ↗

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.Semantic proximity Read ↗

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.Semantic proximity Read ↗

Latest advances in adult gastrointestinal stromal tumors.Semantic proximity Read ↗

Precision medicine in gastrointestinal stromal tumors.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?Semantic proximity Read ↗

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumorsSemantic proximity Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisSemantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Progress in determining response to treatment in gastrointestinal stromal tumor.Semantic proximity Read ↗

Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.